Understanding and managing ischemic stroke.
暂无分享,去创建一个
P. Barber | G. Sutherland | A. Buchan | R. Auer | R N Auer | A M Buchan | G R Sutherland | P A Barber
[1] R. Silver,et al. Non‐NMDA glutamate receptor occupancy and open probability at a rat cerebellar synapse with single and multiple release sites. , 1996, The Journal of physiology.
[2] M. Fisher. The Travails of Neuroprotective Drug Development forAcute Ischemic Stroke , 1998, European Neurology.
[3] P. Deyn,et al. Treatment of Acute Ischemic Stroke With Piracetam , 1997 .
[4] G. Albers,et al. Safety, Tolerability, and Pharmacokinetics of the N-Methyl-d-Aspartate Antagonist Dextrorphan in Patients With Acute Stroke , 1995 .
[5] K. Hossmann,et al. Neurobiology of ischemic brain damage , 1993 .
[6] R. Rothlein,et al. Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Model , 1993, Experimental Neurology.
[7] G. Schlaug,et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion‐weighted magnetic resonance imaging , 1997, Annals of neurology.
[8] C. Starmer,et al. Na channel kinetics remain stable during perforated-patch recordings. , 1992, The American journal of physiology.
[9] M. Chopp,et al. Postischemic Administration of an Anti‐Mac‐1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats , 1994, Stroke.
[10] L. Wilkins. Practice Advisory , 1996, Neurology.
[11] T. Olsen,et al. Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model , 1999, BMJ.
[12] C. Chiamulera,et al. Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. , 1992, European journal of pharmacology.
[13] E. Haley. High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators. , 1998, Stroke.
[14] David G. Norris,et al. Evolution of Regional Changes in Apparent Diffusion Coefficient during Focal Ischemia of Rat Brain: The Relationship of Quantitative Diffusion NMR Imaging to Reduction in Cerebral Blood Flow and Metabolic Disturbances , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] P D Lyden,et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. , 1996, Circulation.
[16] B. Siesjö,et al. Acidosis Induced by Hypercapnia Exaggerates Ischemic Brain Damage , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] K. Lees,et al. Duration of neuroprotective treatment for ischemic stroke. , 1998, Stroke.
[18] P. Dorman,et al. Recently Developed Neuroprotective Therapies for Acute Stroke , 1996 .
[19] J. Kurhanewicz,et al. Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. , 1990, AJNR. American journal of neuroradiology.
[20] R. Rothlein,et al. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. , 1991, Stroke.
[21] B. Davidson,et al. Attenuation of Stroke Size in Rats Using an Adenoviral Vector to Induce Overexpression of Interleukin-1 Receptor Antagonist in Brain , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] R R Edelman,et al. Clinical Outcome in Ischemic Stroke Predicted by Early Diffusion-Weighted and Perfusion Magnetic Resonance Imaging: A Preliminary Analysis , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[23] J Kucharczyk,et al. In vivo diffusion-perfusion magnetic resonance imaging of acute cerebral ischemia. , 1991, Canadian journal of physiology and pharmacology.
[24] S. Budd,et al. Mechanisms of neuronal damage in brain hypoxia/ischemia: focus on the role of mitochondrial calcium accumulation. , 1998, Pharmacology & therapeutics.
[25] S. Warach,et al. Magnetic Resonance Imaging of Acute Stroke , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[26] C. Sudlow,et al. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. , 1997, Stroke.
[27] B. Dardzinski,et al. Multislice diffusion mapping for 3-D evolution of cerebral ischemia in a rat stroke model , 1995, Neurology.
[28] W. Paschen,et al. Multiparametric Imaging of Blood Flow and Metabolism after Middle Cerebral Artery Occlusion in Cats , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[29] J. Grotta. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. , 1997, Stroke.
[30] Caroline Leigh Watkins. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997 .
[31] G. Mies,et al. Ischemic Thresholds of Cerebral Protein Synthesis and Energy State following Middle Cerebral Artery Occlusion in Rat , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[32] G. Sutherland,et al. Electron Microscopic Evidence against Apoptosis as the Mechanism of Neuronal Death in Global Ischemia , 1999, The Journal of Neuroscience.
[33] G. D. del Zoppo,et al. P‐Selectin and Intercellular Adhesion Molecule‐1 Expression After Focal Brain Ischemia and Reperfusion , 1994, Stroke.
[34] A. Clark,et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia , 1997, Neuroscience Letters.
[35] H. Diener. Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic Stroke , 1998, Cerebrovascular Diseases.
[36] K. Hossmann,et al. Cortical Negative DC Deflections following Middle Cerebral Artery Occlusion and KCl-Induced Spreading Depression: Effect on Blood Flow, Tissue Oxygenation, and Electroencephalogram , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[37] B. Siesjö,et al. Thresholds in cerebral ischemia - the ischemic penumbra. , 1981, Stroke.
[38] T. Wieloch,et al. Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. , 1996, Stroke.
[39] G. Mies,et al. MK-801, a glutamate antagonist, lowers flow threshold for inhibition of protein synthesis after middle cerebral artery occlusion of rat , 1993, Neuroscience Letters.
[40] K. Hossmann. Disturbances of cerebral protein synthesis and ischemic cell death. , 1993, Progress in brain research.
[41] G. Sutherland,et al. 23Na nuclear magnetic resonance spectral changes during and after forebrain ischemia in hypoglycemic, normoglycemic, and hyperglycemic rats. , 1996, Stroke.
[42] K. S. Lee,et al. Intraischemic hypothermia attenuates neutrophil infiltration in the rat neocortex after focal ischemia-reperfusion injury. , 1996, Neurosurgery.
[43] G. Hankey. One Year after CAPRIE, IST and ESPS 2 , 1998, Cerebrovascular Diseases.
[44] Jin-Moo Lee,et al. The changing landscape of ischaemic brain injury mechanisms , 1999, Nature.
[45] L. Squire,et al. Enduring memory impairment in monkeys after ischemic damage to the hippocampus , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[46] Davis Dr. Effects of alcohol on the fetus. , 1978, The New England journal of medicine.
[47] K. Lees,et al. Does neuroprotection improve stroke outcome? , 1998, The Lancet.
[48] M. Miller,et al. Polyethylene glycol-conjugated superoxide dismutase in focal cerebral ischemia-reperfusion. , 1993, The American journal of physiology.
[49] N. Wahlgren,et al. The clomethiazole acute stroke study (CLASS): efficacy results in 545 patients classified as total anterior circulation syndrome (TACS). , 1999, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[50] R R Edelman,et al. Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke , 1997, Neurology.
[51] B. Siesjö,et al. Penumbral Tissues Salvaged by Reperfusion Following Middle Cerebral Artery Occlusion in Rats , 1992, Stroke.
[52] C. Iadecola,et al. Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats. , 2000, Stroke.
[53] M E Moseley,et al. High-Speed MR Imaging of Ischemic Brain Injury following Stenosis of the Middle Cerebral Artery , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[54] N. Rothwell,et al. Neuroprotective Effects of Human Recombinant Interleukin-1 Receptor Antagonist in Focal Cerebral Ischaemia in the Rat , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[55] G. D. del Zoppo,et al. Inhibition of Polymorphonuclear Leukocyte Adherence Suppresses No‐Reflow After Focal Cerebral Ischemia in Baboons , 1992, Stroke.
[56] U. Zwiener,et al. The distribution of normal brain water content in Wistar rats and its increase due to ischemia , 1997, Brain Research.
[57] D. Warner,et al. In vivo Models of Cerebral Ischemia: Effects of Parenterally Administered NMDA Receptor Glycine Site Antagonists , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[58] K. Lees,et al. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. , 1995, Stroke.
[59] B. Grøgaard,et al. Delayed Hypoperfusion after Incomplete Forebrain Ischemia in the Rat. The Role of Polymorphonuclear Leukocytes , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[60] J. Grotta. Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapy , 1995, Journal of internal medicine.
[61] P. Sandercock,et al. Low-Molecular-Weight Heparins or Heparinoids Versus Standard Unfractionated Heparin for Acute Ischemic Stroke (Cochrane Review) , 2002, Stroke.
[62] A. Hakim. The Cerebral Ischemic Penumbra , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[63] T. L. Davis,et al. Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. , 1996, Radiology.
[64] G. Hankey,et al. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations* , 1999, The Lancet.
[65] Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.
[66] M. Fisher,et al. Acute ischemic stroke therapy. A clinical overview. , 1997, European Neurology.
[67] Fred Plum,et al. Temporal profile of neuronal damage in a model of transient forebrain ischemia , 1982, Annals of neurology.
[68] J. Davies. Remacemide hydrochloride: a novel antiepileptic agent. , 1997, General pharmacology.
[69] W. Hacke,et al. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. , 1998, Stroke.
[70] N. Wahlgren,et al. Clomethiazole Acute Stroke Study (CLASS) Results of a Randomized, Controlled Trial of Clomethiazole Versus Placebo in 1360 Acute Stroke Patients , 1998 .
[71] Y. Itoyama,et al. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. , 1995, Stroke.
[72] Wei Li,et al. Fast magnetic resonance diffusion‐weighted imaging of acute human stroke , 1992, Neurology.
[73] S. Theander,et al. Calcium, Excitotoxins, and Neuronal Death in the Brain a , 1989, Annals of the New York Academy of Sciences.
[74] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.
[75] P A Wolf,et al. Epidemiology of stroke. , 2004 .
[76] P. Sandercock,et al. Hospital services for patients with acute stroke in the United Kingdom: the Stroke Association Survey of consultant opinion. , 1995, Age and ageing.
[77] C J Epstein,et al. Manganese Superoxide Dismutase Mediates the Early Release of Mitochondrial Cytochrome C and Subsequent DNA Fragmentation after Permanent Focal Cerebral Ischemia in Mice , 1999, The Journal of Neuroscience.
[78] Peter Sandercock,et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.
[79] B. Siewert,et al. Acute human stroke studied by whole brain echo planar diffusion‐weighted magnetic resonance imaging , 1995, Annals of neurology.
[80] Dwaine F. Emerich. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? , 1999 .
[81] D. Choi,et al. Neuroprotective Effect of Hypothermia in Cortical Cultures Exposed to Oxygen‐Glucose Deprivation or Excitatory Amino Acids , 1994, Journal of neurochemistry.
[82] Fangyi Zhang,et al. Delayed Reduction of Ischemic Brain Injury and Neurological Deficits in Mice Lacking the Inducible Nitric Oxide Synthase Gene , 1997, The Journal of Neuroscience.
[83] Obrenovitch Tp. The ischaemic penumbra: twenty years on. , 1995 .
[84] R. Koehler,et al. Monoclonal Leukocyte Antibody Does Not Decrease the Injury of Transient Focal Cerebral Ischemia in Cats , 1992, Stroke.
[85] P. Young,et al. Tumor necrosis factor-alpha expression in ischemic neurons. , 1994, Stroke.
[86] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[87] G. Sutherland,et al. Forebrain Ischemia in Diabetic and Nondiabetic BB Rats Studied With 31P Magnetic Resonance Spectroscopy , 1992, Diabetes.
[88] M. O'Neill,et al. Neuroprotective effects of a systemically active Group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia , 1998, Neuroreport.
[89] M Hoehn-Berlage,et al. Relationship between diffusion-weighted MR images, cerebral blood flow, and energy state in experimental brain infarction. , 1995, Magnetic resonance imaging.
[90] John Whitehead,et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial , 2000, The Lancet.
[91] J. Relton,et al. Peripheral Administration of Interleukin-1 Receptor Antagonist Inhibits Brain Damage after Focal Cerebral Ischemia in the Rat , 1996, Experimental Neurology.
[92] J. Povlishock,et al. Cytochemical detection of superoxide in cerebral inflammation and ischemia in vivo. , 1992, The American journal of physiology.
[93] M. Moskowitz,et al. Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.
[94] A. Buchan,et al. Delayed Treatment with AMPA, but Not NMDA, Antagonists Reduces Neocortical Infarction , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[95] K. Lees. Cerestat and other NMDA antagonists in ischemic stroke , 1997, Neurology.
[96] G. Zoppo. Why do all drugs work in animals but none in stroke patients ? 1 Drugs promoting cerebral blood flow , 1995 .
[97] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[98] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[99] B. J. Sussman,et al. Thrombolysis with fibrinolysin in cerebral arterial occlusion. , 1958, Journal of the American Medical Association.
[100] M. Kaste,et al. The European Cooperative Acute Stroke Study (ECASS) , 1993 .
[101] K. Muir,et al. Neuroprotection for acute stroke: making clinical trials work. , 1999, Stroke.
[102] D. Choi. Cerebral hypoxia: some new approaches and unanswered questions , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[103] C. Portera-Cailliau,et al. Non‐NMDA and NMDA receptor‐mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: Further evidence for an apoptosis‐necrosis continuum , 1997, The Journal of comparative neurology.
[104] B. Palmier,et al. Changes in oxidative stress, iNOS activity and neutrophil infiltration in severe transient focal cerebral ischemia in rats , 2002, Brain Research.
[105] C. Portera-Cailliau,et al. Excitotoxic neuronal death in the immature brain is an apoptosis‐necrosis morphological continuum , 1997, The Journal of comparative neurology.
[106] S. Cory,et al. The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.
[107] K. Herholz,et al. Effect of Piracetam on Cerebral Glucose Metabolism in Alzheimer's Disease as Measured by Positron Emission Tomography , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.